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aa = Amino acid 
DM = Diabetes mellitus 
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eGFR = Estimated glomerular filtration rate 
EMA = European Medicines Agency 
FDA = Food and Drug Administration, United States 
FTO = Fat mass and obesity-associated gene 
GI = Gastrointestinal tract 
GIP = Gastric inhibitory hormone 
GLP-1 = Glucagon-like peptide 1 
HbA1c = Glycated hemoglobin 
IGF2BP = Insulin growth factor 2 mRNA-binding protein 
IRS-1 = Insulin receptor substrate 1 
PCT     = Proximal convoluted tubules 
PPAR-γ 2 = Peroxisome proliferator-activated receptor gamma 2 
q.d. = Daily 
SGLT1 = Sodium glucose co-transporter 1  
SGLT2 = Sodium glucose co-transporter 2  
T1DM = Type 1 diabetes mellitus 
T2DM = Type 2 diabetes mellitus 
TCF7L2 = Transcription factor-7–like 2  








































Introduction: More than 424 million adults have diabetes mellitus (DM). This number is 
expected to increase to 626 million by 2045. The majority (90-95%) of people with DM has type 
2-diabetes (T2DM). The continued prevalence of DM and associated complications has 
prompted investigators to find new therapies. One of the most recent additions to the anti-
diabetic armamentarium are inhibitors of sodium-glucose co-transporters 1 and 2 (SGLT1, 
SGLT2).  
Areas covered: The authors review the status of SGLT2 inhibitors for the treatment of T2DM 
and place an emphasis on those agents in early phase clinical trials. Data and information were 
retrieved from American Diabetes Association, Diabetes UK, ClinicalTrials.gov, PubMed, and 
Scopus websites. The keywords used in the search were T2DM, SGLT1, SGLT2 and clinical 
trials. 
Expert opinion: The benefits of SGLT inhibitors include reductions in serum glycated 
haemoglobin (HbA1c), body weight, blood pressure and cardiovascular and renal events. 
However, SGLT inhibitors increase the risk of genitourinary tract infections, diabetic 
ketoacidosis and bone fractures. The development of SGLT inhibitors with fewer side effects and 
as combination therapies are the key to maximizing the therapeutic effects of this important class 
of anti-diabetic drug.  
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Article Highlights 
 Diabetes mellitus currently affects 424 million people globally 
 Short and long-term complications of diabetes mellitus (DM) are still common in spite of 
the large pool of medications available to treat the disease  
 SGLT1 and 2 inhibitors block the reabsorption of glucose from the intestinal mucosa and 
proximal convoluted tubules, respectively  
 SGLT1 and 2 inhibitors cause significant reductions in body weight, blood pressure and 
HbA1c level 
 SGLT2-induced reduction in cardiovascular and renal events in T2DM patients with 
well-established CVD and kidney disease, is an added advantage for this class of 
hypoglycemic agents 
 Dual SGLT inhibitors with fewer side effects have great potential to succeed as a major 
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1. Introduction 
 
1.1. Diabetes mellitus 
 
Diabetes mellitus (DM) is a chronic metabolic disease that affects more than 424 million adults 
worldwide [1]. This number is projected to increase to almost 627 million in the next 25 years 
[1]. Type 2 DM is the most common variety and accounts for 90-95% of all cases of DM [2]. 
T2DM is more prevalent in adults and older age groups. T2DM may be caused by a variety of 
factors including but not limited to defective insulin secretion, resistance to insulin, structural 
changes in insulin molecule, or anomaly in the configuration of GLUT4 receptor [3]. These 
anomalies may lead to chronic hyperglycemia. The severity of T2DM within and between ethnic 
groups may be due to mutations in or abnormal genes regulating glucose metabolism. These 
genes include: FTO, PPAR-γ 2, IGF-2 binding protein, IRS-1, TCF7L2, and several others [4].  
The multifactorial nature of the etiology and pathogenesis of T2DM makes it difficult to treat 
with monotherapy, posing a strong challenge to researchers and clinicians alike. The continued 
increase in the prevalence and complications associated with T2DM has arouses the urge to find 
new and more effective drugs to treat and prevent T2DM and its complications. Sodium-glucose 
co-transporters 1 and 2 inhibitors were discovered in the light of these efforts to find a more 
potent drug for the effective treatment of T2DM. 
 
1.2. History and discovery of SGLT1 and SGLT2  
 
The human SGLT1 is a 664-amino acid (aa) protein that is located on chromosome 22 at “q13.1” 
[5]. SGLT2 protein on the other hand is composed of 672 aa and is located on chromosome 16 at 
“p11.2” [6]. The discovery of SGLT went as far back as 1930s when Chasis et al [7] examined 
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by the glomerulus is reabsorbed by the proximal convoluted tubules (PCT), a phenomenon that 
prevents the release of glucose into urine in a normal, functioning kidney. Chasis et al [7] 
showed that phlorizin itself was capable of preventing the reabsorption of glucose from the PCT. 
The period was followed by several years of investigations on the cellular and molecular 
regulation of glucose reabsorption from the PCT and the small intestine using a variety of 
models including but not limited to preparations of intestinal microvilli membrane vesicles [8].  
Additional studies reported that mutations of SGLT2 genes resulted in severe glycosuria [6]. 
Moreover, it was also observed that animals lacking the SGLT genes were unable to reabsorb 
glucose from the PCT [9]. All of these observations support the role of SGLT in the regulation of 
glucose reabsorption from the PCT (SGLT2) and the intestinal mucosa (SGLT1) to blood 
circulation. In the late 1980s, Ernest Wright and his co-workers cloned SGLT genes and 
concluded that SGLT1 is more predominant in the small intestine while SGLT2 is responsible 
for the reabsorption of glucose through the brush border of the renal PCT [10]. 
 
The cloning of the genes responsible for the reabsorption of glucose, especially from the renal 
PCT marked a turning point in SGLT biology and paved the way for intensive investigations as 
to what will happen to DM patients if these proteins (SGLTs) were inhibited. The rational behind 
this approach is that reduction of hyperglycemia, a major inducer of oxidative stress, will reduce 
some of the symptoms and complications associated with DM [11]. The first known inhibitor of 
SGLTs is phlorizin, a chalcone, first extracted from the bark of the roots of apple trees by De 
Koninck in 1835 [12]. The name of this bitter-tasting phlorizin is derived from the Greek word 
for “root” [13].  
 
The early 1940s marked an important milestone in the history of SGLT inhibitors, when the 
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They showed that phlorizin is a 2′-glucoside of phloretin, a flavonoid with antipyretic properties 
[13].  Although, von Mering has noted as far back as 1886, that phlorizin causes glycosuria [15], 
it was not until the 1980s that the mechanism by which SGLT reabsorbs glucose through brush 
borders epithelial cells was identified and characterized [16]. All of these efforts on the biology 
of SGLTs to find a role for it in the treatment of DM have led to the discovery of the first SGLT 
inhibitor in 2000 [17] and eventually the first specific SGLT2 inhibitor in 2008 [18]. 
Danagliflozin, the first gliflozin to be discovered, was approved for the treatment of T2DM in 




2. Mechanisms of actions, benefits and adverse effects SGLT1 and 2 inhibitors 
 
2.1. SGLT1 inhibitors 
 
SGLT1 inhibitors prevent the absorption of glucose from the microvilli of the enterocytes of the 
small intestine, and to a lesser extent from the brush border of the epithelial cells of renal PCT 
[6]. In contrast to SGLT2, SGLT1 is located in the apical plasma membrane of cells in many 
organs, including the S3 segment of the PCT, gastrointestinal tract, heart (capillary endothelium), 
and red blood cells, lung (alveolar and Clara or club cells), liver (biliary epithelium) [20, 21]. 
 
 
2.2. SGLT2 inhibitors 
 
SGLT2 inhibitors block the reabsorption of glucose from the first segment (S1) of PCT. Since 
SGLT2 are also found on cells of the liver and the brain [22], they are able to potentially prevent 
the influx of glucose into these tissues. In contrast to SGLT1, SGLT2 prevents the reabsorption 
of more than 90% of glucose filtered through the glomerular basement membrane compared to 
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SGLT inhibitors, therefore, competitively block SGLT protein located on the apical surfaces of 
the cells of the renal PCT and intestinal mucosa, capillary endothelium of the myocardium, 
alveolar and club cells of the lung, and the biliary epithelium.  
 
2.3. Dual SGLT1-SGLT2 inhibitors 
Dual SGLT1-SGLT2 inhibitors, such as sotagliflozin and licogliflozin, are capable of preventing 
glucose uptake from the brush border of the columnar cells of the small intestine in addition to 
their ability to impede the absorption of glucose from the first, initial, segment (S1) of the PCT. 
This property of dual SGLT1-SGLT2 inhibitors adds another agonistic effect in the amelioration 
of hyperglycemia. The use of dual SGLT1-SGLT2 inhibitors comes with advantages and 
disadvantages. By also inhibiting SGLT1 (in addition to SGLT2), sotagliflozin, lowers the 
glucose upsurge seen immediately after a meal [23]. Sotagliflozin [23] and licogliflozin [24] also 
facilitates GLP-1 release from the L-cells of the GIT [23]. Advantages and disadvantages of dual 
SGLT1-SGLT2 inhibitors versus selective SGLT2 inhibitors include the following [23, 24, 25]: 
Advantages  
 Reduces postprandial glucose surge 
 Increases GLP-1 release from the cecum 
 Inhibits DPP-4, thereby prolonging the lifespan of GLP-1 
 Could serve as adjuvant therapy in the treatment of Type 1 DM 
 
Disadvantages [26] 
 Causes adverse GIT effects like diarrhea   
 Induces a higher rate of diabetic ketoacidosis 












Information Classification: General 
2.4. Advantages of SGLT1 and 2 inhibitors 
 
SGLT cause significant reductions in: 
o blood glucose level 
o HbA1c 
o body weight  
o blood pressure  
o reduced triglycerides 
Since these parameters are common co-morbidities in T2DM, reductions in all of them would 
reduce complications associated with DM [11]. Hyperglycemia is a major inducer of oxidative 
stress. It is well known that oxidative stress induces glycation of proteins, which in turn leads to 
malfunction of important enzymes in the body [11]. 
 
2.5. Side effects of SGLT1 and 2 inhibitors 
 
o Polyuria - due to the osmotic nature of glucose retained in urine 
o Infections of the urinary and genital tracts – because large quantity of glucose acts as a 
media for the growth of fungi in the urinary tract. 
o Hypotension – This is not a major adverse effect of SGLT2 but hypotension may occur 
when combined with loop diuretics [27]. 
o Hypoglycemia –This may occur if SGLT2 inhibitors is combined with insulin or 
sulfonylureas  
o Lower limb amputation – hypovolemia leading to blood viscosity, venous 
thromboembolism. This is probably not a class effect because a meta-analysis of 27 
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increased with SGLT2 inhibitors, it was only significant for patients taking canagliflozin 
[28, 29] 
o Increased risk of bone fracture – calcium and phosphate ion imbalance? [30]   
o Acute kidney injury – Probably due to SGLT-induced disturbance in the regular and 
physiological function of the kidney and hypovolemia [30] 
Other side effects reported for SGLT2 inhibitors include nausea, polydipsia, arthralgia, 
angioedema, perineal necrotizing fasciitis, Fournier gangrene, diabetic ketoacidosis and 
hyperkalemia [30, 31].  
 
3. SGLT1 and 2 inhibitors approved by the FDA and EMA 
3. 1. Dapagliflozin 
Dapagliflozin is a selective, FDA-approved, SGLT2 inhibitor for the treatment of T2DM in 
combination with regimens of diet, exercise and anti-diabetic drugs. Dapagliflozin, produced 
through a joint venture by Bristol-Myers Squibb and AstraZeneca, can be given per os at a dose 
of 5-10 mg per day [32]. Reports from DECLARE-TIMI 58, a randomized controlled study 
involving 17,160 T2DM patients with established cardiovascular disease (CVD) or risks of 
CVD, showed that danagliflozin treatment for four years resulted in significantly lower 
cardiovascular death rate. It also resulted in a reduced rate of heart failure related hospitalization 
[33]. Additional data from the DECLARE-TIMI 58 randomized trial also showed that 
danagliflozin can prevent and lower the progression of renal disease in T2DM patients with and 
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3. 2. Canagliflozin 
Canagliflozin, developed by Johnson & Johnson, USA, was approved in 2013 by the FDA 
(USA) for the treatment of T2DM. The CANVAS (Canagliflozin Cardiovascular Assessment 
Study), a large study spearheaded in Australia involving more than 10,000 patients who were 
given canagliflozin randomly versus placebo, showed a significantly lower risk of cardiovascular 
illness coupled with a marked reduction in the rate of hospitalization for heart and kidney failure 
[35, 36]. This study lasted over four years, indicating that some of the long-term effects of 
canagliflozin were also in display. In a similar trend, CREDENCE, a recent randomized 
controlled study examining the effect of canagliflozin on cardiovascular and renal outcome in 
patients with T2DM, showed that this SGLT2 inhibitor improves cardiovascular (e.g. rate of 
heart failure hospitalization, non-fatal myocardial infarction etc.) and renal outcomes (e.g. 
kidney failure [37]. In a recently published double blind, randomized CREDENCE Trial, 
canagliflozin was reported to reduce the risk of cardiovascular and renal failure in T2DM 
subjects with renal disease [37, 38]. Canagliflozin can be prescribed for oral administration (100-
300 mg tablets). Fig 1, Table 1. 
 
3.3. Empagliflozin 
Empagliflozin, another strong inhibitor of SGLT2, is a product of a joint venture between 
Boehringer Ingelheim and Eli Lilly Pharmaceutical companies. In the EMPA-REG OUTCOME 
randomized controlled trial involving a large number (>7,000) of patients, empagliflozin was 
reported to significantly reduce cardiovascular disease risks, three years after treatment [39]. 
Empagliflozin was approved for the treatment of T2DM and for the reduction of death from 
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profile may be due to the fact that empagliflozin increased HDL level and reduced blood 
triglyceride concentration as reported in a more recent EMPA-REG OUTCOME Study [41]. 
Indeed, another recent study shows that empagliflozin can reduce cardiovascular death risks by 
as much as 38% [42] and delay the progression of chronic kidney disease in T2DM patients with 
or without cardiac failure [43]. This shows that empagliflozin has cardio-renoprotective effect 
similar to that of dapagliflozin and canagliflozin, indication that this is most likely a class effect. 
Empagliflozin is given per os at 10 or 25 mg q.d. Fig 1, Table 1. 
 
3.4. Ertugliflozin 
In a clinical trial involving more than 400 patients, ertugliflozin was reported to significantly 
reduce fasting plasma glucose, blood pressure and total body weight, 26 weeks after the 
administration of ertugliflozin when compared placebo. It was of particularly interesting to note 
that ertugliflozin was safe in patients with chronic renal disease. Moreover, hypoglycemia and 
infections of the urinary and genital tracts were not markedly different between treated and 
placebo groups [44]. However, the volume deficit that was observed in ertugliflozin-treated 
group [44] was higher relative to placebo. The recommended daily dose of ertugliflozin is 5-15 
mg. VERTIS MONO Trial, however, showed that the rate of fungal infection of the genitalia was 
significantly higher in patients taking ertugliflozin when compared to placebo [45]. A 
randomized, double blind, placebo-controlled interventional clinical trial (VERTIS-CV) 
conducted to examine the effectiveness and safety of ertugliflozin on cardiovascular outcomes in 
a pool of T2DM 8,000 patients is currently ongoing and will be completed in December 2019, 
after six years of intensive study [46, 47]. Ertugliflozin, approved by the FDA on December 22, 

















4. SGLT 1 and 2 inhibitors under investigation (not approved by the FDA and EMA) 
 
4.1. Ipragliflozin 
Ipragliflozin was the first SGLT2 inhibitor approved for the treatment of T2DM in Japan in 
2014. It was produced by a joint venture between Astellas Pharma and Kotobuki Pharmaceutical 
in Japan. In a large Japanese, post-marketing open study, examining the effect of ipragliflozin in 
more than 8,000 patients, it was reported that this drug has similar efficacy when compared to 
currently available SGLT2 inhibitors. The investigators showed that ipragliflozin could 
significantly reduce blood glucose level, body weight, HbA1c, blood pressure, and even LDL-
cholesterol. The side effects recorded for this drug are similar to those of SGLT2 inhibitors in the 
market and include renal and urinary tract infections [48]. Ipragloflozin has not received the 
approval of the FDA in the USA [49, 50]. Ipragliflozin is given orally as 50 mg once daily. Fig 
2A, Table 2. 
4.2. Tofogliflozin 
Tofogliflozin is a product of Chugai Pharmaceutical Company, Japan. It was developed in 
conjunction with Sanofi-Aventis and Kowa Pharmaceuticals and approved for the treatment of 
T2DM in 2014 in Japan. In a large post-marketing open study involving more than 6,897 
patients, tofogliflozin was reported to markedly reduce HbA1c and bodyweight. In addition to 
the beneficial effects of tofogliflozin, polyuria, increased risk infections of the urinary and 
genital tracts was also observed [51]. The FDA has not yet approved tofogliflozin, and it is 
therefore still considered an investigational drug in the USA.  The recommended dose of 
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4.3. Sotagliflozin  
Sotagliflozin is product of Sanofi and Lexicon Pharmaceuticals and it is currently under 
consideration for the treatment of T1DM by the European Medicines Agency [52]. Sotagliflozin 
inhibits both SGLT1 and SGLT2 in the kidney and the intestine leading to a marked reduction in 
HbA1c, body weight, blood pressure, and post-prandial blood glucose. The role of sotagliflozin 
is currently being explored in several clinical trials [53, 54, 55]. A recent meta-analysis of 
randomized control trials showed that sotagliflozin increased the rate of diabetic ketoacidosis 
when compared to placebo but the rate of UTI did not significantly differ when compared to 
control [56]. This indicates that dual SGLT inhibitors may cause fewer infections associated with 
the urinary tract. The recommended daily dose of sotagliflozin is 200 mg q.d., but could be 





Luseogliflozin, when administered at 2.5 mg q.d. for a year to a cohort of 37 T2DM patients in 
Japan (LIGHT Study), caused large reductions in fasting blood glucose level, HbA1c, body 
weight, triglycerides and blood pressure (systolic and diastolic). However, the blood 
concentration of ketone bodies was increased over the same period [57]. Reports from LEAD 
Trial showed that luseogliflozin, administered for 8 months, caused a marked reduction in the 
lipid content of liver of patients suffering from non-alcoholic fatty liver disease [58]. Although 
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received the approval by the FDA [59]. The recommended dosage for luseogliflozin is 5 mg q.d. 
but it effect may be less effective in severe renal failure [60]. Fig 2A, Table 2. 
 
4.5. Remogliflozin 
Remogliflozin etaborate is a pro-drug of remogliflozin, a selective inhibitor of SGLT2 protein. It 
prevents the reabsorption of glucose from the epithelium of the PCT. It is a drug developed by 
Avolynt Inc (Research Triangle Park, North Carolina, USA). Remogliflozin is currently 
undergoing clinical trials for the treatment of T2DM and non-alcoholic steatohepatitis. 
Remogliflozin has been reported to reduce blood glucose and HbA1c levels [61]. The phase 2b 
trial was completed in 2018 [62]. It is well tolerated but with a relatively short half-life of just 2-
4 h [63, 64]. In contrast to the advantages of remogliflozin, it also causes side effects (e.g. 
urinary and genital tract fungal infections, syncope) [65] that are similar to those seen with other 
SGLT2 inhibitors. Although remogliflozin was approved for the treatment of T2DM in India in 
July 2019, it is not yet licensed for use in the USA. The daily dosage of remogliflozin 200 mg is 
two doses [64].  Fig 2A, Table 2 
4.6. Velagliflozin 
 
This SGLT2 inhibitor was developed by Boeringer Ingelheim (Germany) and currently used on 
veterinary subjects. It was concluded that 0.3 mg/kg body weight of velagliflozin per os for 16 
weeks to ponies was safe to use [66]. It is unknown whether velagliflozin could eventually be of 















Information Classification: General 
In a study that examined the effect of henagliflozin on T2DM, it was reported that this SGLT2 
inhibitor reduced plasma glucose level in a dose-dependent manner. No severe side effects were 
reported for this small group of T2DM patients with doses ranging from 5 - 20 mg per day [67]. 
The authors suggested that henagliflozin is suitable for, once daily, regimen [67]. Due to the 
small number of patients in this study it is likely premature to rule out adverse effects that are 
related to SGLT2 inhibitors in general. Two phase III clinical trials conducted by Hengrui 
Medicine Co (Jiangsu, China) that examine the impact of henagliflozin on T2DM is currently 




Bexagliflozin, like most of the SGLT2 inhibitors, is a phenolic glycoside. More than 10 clinical 
trials have been completed on the effect of bexagliflozin on the treatment of T2DM. One of the 
few published results includes a small study presented at the Meeting of the American Society 
for Nephrology, Kidney Week in San Diego in October 2018. In a study that examined 312 
patients suffering from T2DM and end stage kidney disease, bexagliflozin, was reported to 
significantly reduce HbA1c level, body weight, and blood pressure in addition to its glucose 
lowering effects. In a more recent report, 20 mg/day of bexagliflozin, administered over a 96-
week period, was well tolerated and induced significant reduction in blood pressure, weight loss 
and HbA1c level [69]. Fig 2B, Table 2. 
 
TABLE 2 HERE 
4.10. Licogliflozin 
Licogliflozin is a dual SGLT (1 and 2) inhibitor, currently under development by Norvatis 
Institute of Medical Research (Basel, Switzerland). In a recent report of open clinical study, it 
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12 weeks, lowers postprandial glucose spike, and weight. In addition, licogliflozin is safe, well 
tolerated and was able to improve metabolic parameters and incretin (GLP-1, GIP) levels. 
However, adverse effects (diarrhea, loose stools) associated with SGLT1 inhibitors were 
significantly more profound compared to placebo [24]. He et al [24] concluded that licogliflozin 
appears to be more effective than sotogliflozin, another dual SGLT inhibitor in the maintenance 
of glycemic control because licogliflozin can completely block SGLT1 when given in high doses 





Despite advanced technology, current knowledge and the many medications available to the 
population, the number of people with diabetes mellitus (DM) continues to rise. In addition to 
the increased prevalence, the associated complications of DM continue to take its toll on the 
quality of life of the patients and place an even a greater burden on the healthcare system. The 
introduction of SGLT2 inhibitors into the arsenal of anti-diabetic drugs available is a response to 
these challenges. The major advantage of SGLT2 inhibitors includes their ability to significantly 
reduce hyperglycaemia, body weight and blood pressure. These reductions, including SGLT2-
induced volume depletion, contribute to the lowering of cardiovascular and renal risks.  
 
 
6. Expert Opinion 
 
The ability of SGLT1 and 2 inhibitors to significantly reduce hyperglycemia, HbA1c, body 
weight, and blood pressure is a major advantage over many other classes of anti-diabetic drugs. 
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cardiovascular events, cancer and many others. SGLT2 inhibitors specifically prevent the 
reabsorption of glucose from PCT, thereby reducing hyperglycemia. Hyperglycemia is known to 
induce oxidative stress [11]. Oxidative stress in turn results in a cascade of events leading to the 
production of reactive oxygen species and formation of advanced glycated end products and 
several other molecular mechanisms that will cause long-term complications [11].  
 
In contrast to the benefits of SGLT2 inhibitors, there are many adverse effects associated with 
this group of anti-diabetic drugs. SGLT2 inhibitors have been reported to cause polyuria, 
increase the risk of urinary and genital tract infections, hypotension, hypoglycemia, increased 
level of LDL-cholesterol [41], lower limb amputation (with canagliflozin), increase 
predisposition to developing bone fractures [29].  Other adverse effects associated with the use 
of SGLT2 inhibitors include nausea, polydipsia, arthralgia, angioedema, perineal necrotizing 
fasciitis, and diabetic ketoacidosis [41]. 
These adverse effects attributed to the intake of SGLT2 inhibitors are too many to ignore and 
attempts should made to generate an ideal SGLT2 inhibitor devoid of these severe side effects. In 
spite of these shortcomings, however, the major advantage of SGLT2 inhibitors is that they are 
relatively safe to use [70]. Moreover, several randomized control trials, such as, DECLARE-
TIMI 58 [33], CANVAS [36], EMPA-REG OUTCOME [41-43], VERITAS [47] have all shown 
that SGLT2 inhibitors have cardio-reno-protective properties. In fact, it has been shown that 
SGLT2 inhibitors are more effective than GLP-1 receptor antagonists, in the prevention of 
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The beneficial effects of SGLT2 inhibitors, which are indeed remarkable regarding the overall 
well being of the patients, can therefore be maximized. 
 
Possible ways of mitigating the severity of these adverse effects could include the following: 
 
(a) Development of newer, more potent and more specific generations of SGLT1 and 2 
inhibitors.   
o Several attempts have been made to develop new SGLT 1 and 2 inhibitors with lower 
rate of adverse effect that the current ones. A combined inhibition of SGLT1 and 2, with 
dual SGLT inhibitors may help in the reduction of SGLT2-induced adverse effects, such 
as urinary tract infection [41], hypotension (in patients taking loop diuretics) [27], 
increased risk of bone fracture [30]. Unfortunately, dual SGLT2 inhibitors cause 
significant increases in the number of diarrhea, diabetic acidosis and hypoglycemic 
events [26]. A reduction in the dosage could probably reduce these side effects, since 
dual SGLT inhibitors have been shown to also inhibit DPP-4 and stimulate incretins, such 
as GIP and GLP-1 [24-25]. Inhibition of DPP-4 increases the lifespan of GLP-1, which in 
turn reduces hyperglycemia by stimulating insulin release [72, 73]. 
 
(b) Combination with existing drugs 
The combination of SGLT1 and 2 inhibitors with existing anti-diabetic medications, such 
as metformin, GLP-1 agonists, sulfonylureas and many others, has been generated by 
several pharmaceutical companies. The combination of SGLT2 inhibitors and other anti-
diabetic drugs will facilitate agonistic mechanisms and can help in the reduction of the 
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could be reduced to the bare minimum needed to elicit the required beneficial effect. Li et 
al [74], in their review of six randomized clinical trials, showed that a combination of 
metformin and SGLT2 inhibitor is significantly more effective than other, non-SGLT2 
inhibitor combinations. SGLT2 inhibitors when combined with GLP-1 receptor agonists 
have been reported to be more potent in the reduction of HbA1c, glucose level, body 
weight and blood pressure than when each of the drugs were given alone [55]. 
 
Funding 
The research of the authors is funded by College of Medicine and Health Sciences, 
United Arab Emirates Universityn31M374  
Declaration of interest 
The authors have no relevant affiliations or financial involvement with any organization 
or entity with a financial interest in or financial conflict with the subject matter or 
materials discussed in the manuscript. This includes employment, consultancies, 
honoraria, stock ownership or options, expert testimony, grants or patents received or 
pending, or royalties.  
Reviewer disclosures 
Peer reviewers on this manuscript have no relevant financial or other relationships to 
disclose 
References 
Papers of special note have been highlighted as either of interest (•) or of considerable 
interest (••) to readers 
 
1. Diabetes Atlas. International Diabetes Federation, 8th Edition, 2017 
 
2. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 












Information Classification: General 
 
3. Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes 
mellitus. Ann NY Acad Sci. 2006; 1084: 1-29. 
** A comprehensive review on the epidemiology of diabetes mellitus 
 
4. Ali O. Genetics of type 2 diabetes. World J Diabetes 2013; 4: 114–123. 
 
5. Hediger MA, Turk E, Wright EM. Homology of the human intestinal Na+/glucose and 
Escherichia coli Na+/proline cotransporters. Proc Natl Acad Sci USA 1989; 86:5748-5752. 
 
6. Ghezzi C, Loo DDF, Wright EM.  Physiology of renal glucose handling via SGLT1, 
SGLT2 and GLUT2. Diabetologia 2018; 61: 2087-2097 
*A comprehensive review of the physiology of SLGTs 
 
7. Chasis H, Jolliffe N, Smith HW. The action of phlorizin on the excretion of glucose, 
xylose, sucrose, creatinine and urea by man. J Clin Invest 1933; 12:1083–1090. 
*An excellent expose of the history of SLGTs 
8. Hopfer U, Nelson K, Perrotto J, et al. Glucose transport in isolated brush border membrane 
from rat small intestine. J Biol Chem 1973, 248:25–32 
 
9. Sala-Rabanal M, Hirayama BA, Ghezzi C et al. Revisiting the physiological roles of 
SGLTs and GLUTs using positron emission tomography in mice. J Physiol 2016; 
594:4425-4438.  
 
10. Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloning and cDNA sequencing of the 
Na+/glucose co-transporter. Nature 1987; 330:379–381 
 
 
11. Lotfy M, Adeghate J, Kalasz H, et al. Chronic Complications of Diabetes Mellitus: A Mini 
Review.  Curr Diabetes Rev 2017; 13: 3-10. 
*A comprehensive review on diabetes complications 
 




13. Blaschek W. Natural Products as Lead Compounds for Sodium Glucose Cotransporter 
(SGLT) Inhibitors. Planta Med 2017; 83: 985-993 
 
14. Zemplen G, Bognar R. Synthese des natürlichen Phlorrhizins. Chem Ber 1942; 75: 1040 
15. Von Mering J. Über künstlichen Diabetes. Centralbl Med Wiss 1886; 22: 531 
 
 
16. Lee WS, Wells RG, Hediger MA. The high affinity Na/glucose cotransporter: reevaluation 













Information Classification: General 
 
17. Link JT, Sorensen BK. A method for preparing C-glycosides related to phlorizin. 
Tetrahedron Lett 2000; 41: 9213-9217 
 
18. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: A potent, selective 
renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of 
type 2 diabetes. J Med Chem 2008; 51: 1145-1149 
 
19. Jung CH, Jang JE, Park JY. A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: 
SGLT2 Inhibitor. Diabetes Metab J 2014; 38:261-273.  
 
20. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 
(SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. 
Pharmacol Ther 2013; 139:51-59.  
 
21. Vrhovac I, Balen Eror D, Klessen D et al. Localizations of Na(+)-D-glucose cotransporters 
SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, 
and heart. Pflugers Arch 2015; 467:1881-1898.  
 
 
22. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of Sodium-Glucose Cotransporter 2 
(SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes. Endocr Rev 2011; 32: 515–531 
**A comprehensive review of the effects of SGLT2 inhibitors in diabetes 
 
23. Cariou B, Charbonnel B. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. 
Expert Opin Investig Drugs 2015; 24:1647-1656.  
 
24. He YL, Haynes W, Meyers CD, et al. The effects of licogliflozin, a dual SGLT1/2 
inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab. 
2019; 21:1311-1321.  
 
25. Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current 
outlook and perspectives. Cardiovasc Diabetol. 2019; 18: 20. 
 
26. Garg SK, Henry RR, Banks P, et al. Effects of Sotagliflozin Added to Insulin in Patients 
with Type 1 Diabetes. N Engl J Med. 2017; 377: 2337-2348 
 
 
27. Johnsson K, Johnsson E, Mansfield TA, et al. Osmotic diuresis with SGLT2 inhibition: 
analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med. 
2016;128: 346-355.  
 
 
28. Kmietowicz Z. SGLT2 inhibitors for diabetes are linked to increased risk of lower limb 













Information Classification: General 
 
29. Dicembrini I, Tomberli B, Nreu B, et al. Peripheral artery disease and amputations with 
Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized 
controlled trials. Diabetes Res Clin Pract. 2019; 153:138-144.  
 
 
30. Beitelshees AL, Leslie BR, Taylor SI. Sodium-Glucose Cotransporter 2 Inhibitors: A Case 
Study in Translational Research. Diabetes 2019; 68:1109 -1120.  
 
31. Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier Gangrene Associated With 
Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Post-marketing 
Cases. Ann Intern Med. 2019 May 7. doi: 10.7326/M19-0085. [Epub ahead of print] 
 
32. Kasichayanula S, Liu X, Lacreta F et al. Clinical pharmacokinetics and pharmacodynamics 
of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin 
Pharmacokinet 2014; 53:17-27. 
 
 
33. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 
2 Diabetes. N Engl J Med. 2019; 380: 347-357.  
 
34. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and 
progression of kidney disease in patients with type 2 diabetes: an analysis from the 




35. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal 
Events in Type 2 Diabetes. N Engl J Med 2017; 377:644-657 
**A large study on the effects of SGLT2 in cardiovascular and renal conditions 
 
36. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for Primary and Secondary 
Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin 
Cardiovascular Assessment Study). Circulation. 2018;137:323-334.  
 
 
37. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and Cardiovascular and Renal 
Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary 
Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial. 
Circulation. 2019 Jul 11. doi: 10.1161/CIRCULATIONAHA.119.042007. [Epub ahead of 
print] 
 
38. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 
Diabetes and Nephropathy. N Engl J Med. 2019; 380(24): 2295-2306.  
 
39. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and 












Information Classification: General 
 
40. Sizar O, Talati R. Empagliflozin. SourceStatPearls [Internet]. Treasure Island (FL): 
StatPearls Publishing; 2019 Jan 16. 
 
41. Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 Inhibitors and Cardiovascular Risk: 
Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care. 2016; 39: 717-
725.  
 
42. Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular Mortality Reduction With 
Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. J Am Coll 
Cardiol. 2018;71: 364-367.  
 
43. Butler J, Zannad F, Fitchett D, et al. Empagliflozin improves kidney outcomes in patients 
with or without heart failure. Circ Heart Fail. 2019;12: e005875.  
 
 
44. Grunberger G, Camp S, Johnson J et al. Ertugliflozin in Patients with Stage 3 Chronic 
Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. 
Diabetes Ther 2018; 9: 49–66. 
 
45. Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin 
monotherapy in patients with inadequately controlled T2DM despite diet and exercise: 
VERTIS MONO extension study. Diabetes Obes Metab. 2018; 20:1453-1460.  
 
46. https://clinicaltrials.gov/ct2/show/NCT01986881?term=Ertugliflozin&rank=7 (Assessed on 
July 18, 2019 
 
47. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the 
eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-
CV). Am Heart J. 2018; 206:11-23.  
 
48. Nakamura I, Maegawa H, Tobe K et al. Safety and efficacy of ipragliflozin in Japanese 
patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-
LONG TERM post-marketing surveillance study. Expert Opin Pharmacother 2018;19:189-
201. 
 
49. Veltkamp SA, Kadokura T, Krauwinkel WJ, et al. Effect of Ipragliflozin (ASP1941), a 
novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose 
excretion in healthy subjects. Clin Drug Investig 2011; 31:839-851 
 
50. Ohkura T. Ipragliflozin: A novel sodium-glucose co-transporter 2 inhibitor developed in 
Japan. World J Diabetes 2015; 6: 136–144. 
 
51. Utsunomiya K, Senda M, Kakiuchi S et al. Safety and efficacy of tofogliflozin in Japanese 












Information Classification: General 
interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). J Diabetes 
Investig. 2019 Jan 31. doi: 10.1111/jdi.13017. [Epub ahead of print] 
 
52. Danni T, Cariou B, Buse JB et al. Improved Time in Range and Glycemic Variability With 
Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled 
Analysis of 24-Week Continuous Glucose Monitoring Data From the in Tandem Program. 
Diabetes Care. 2019 Mar 4. pii: dc182149. doi: 10.2337/dc18-2149. [Epub ahead of print] 
 
**A comprehensive survey of the effects of combined Insulin-SGLT2 inhibitors in type 
1 diabetes 
 
53. Cefalo CMA, Cinti F, Moffa S et al. Sotagliflozin, the first dual SGLT inhibitor: current 
outlook and perspectives. Cardiovasc Diabetol 2019;18:20.  
 
54. https://www.diabetes.co.uk/news/2018/mar/sotagliflozin-accepted-by-ema-for-review-in-
treating-people-with-type-1-diabetes-97785339.html {accessed March 15, 2019] 
 
55. Rendell MS. Efficacy and safety of sotagliflozin in treating diabetes type 1. Expert Opin 
Pharmacother 2018; 19:307-315.  
 
 
56. Musso G, Gambino R, professor, Cassader M, et al. Efficacy and safety of dual SGLT 1/2 
inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. 
BMJ. 2019; 365: l1328. 
 
57. Sasaki T, Sugawara M, Fukuda M. Sodium-glucose cotransporter 2 inhibitor-induced 
changes in body composition and simultaneous changes in metabolic profile: 52-week 
prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients 
with Type 2 Diabetes Mellitus) Study. J Diabetes Investig. 2019;10:108-117.  
 
58. Sumida Y, Murotani K, Saito M, et al. Effect of luseogliflozin on hepatic fat content in 
type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm 
trial (LEAD trial). Hepatol Res. 2019;49:64-71.  
 
59. Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs. 2014; 74: 945-950.  
 
60. Samukawa Y, Haneda M, Seino Y et al. Pharmacokinetics and Pharmacodynamics of 
Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes 
With Mild to Severe Renal Impairment. Clin Pharmacol Drug Dev. 2018; 7: 820–828. 
 
 
61. Dash RP, Babu RJ, Srinivas NR. Comparative pharmacokinetics of three SGLT-2 














Information Classification: General 
62. https://finance.yahoo.com/news/avolynt-announces-completion-phase-2b-143600142.html 
(accessed on 16 march 2019) 
 
 




anti-diabetes-drug-remogliflozin-in-india-806614073.html. Accessed on July 18, 2019. 
 
65. Mikhail N. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes 
mellitus. Expert Opin Investig Drugs 2015; 24:1381-1387.  
 
66. Meier A, de Laat M, Reiche D et al. The efficacy and safety of velagliflozin over 16 weeks 
as a treatment for insulin dysregulation in ponies. BMC Veterinary Res 2019;15:65 
 
 
67. Yong X, Wen A, Liu X et al. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a 
Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes 




69. Halvorsen YD, Walford GA, Massaro J, et al. A 96-Week Multinational Randomized 
Double-Blind Parallel-Group Clinical Trial Evaluating the Safety and Effectiveness of 
Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes. Diabetes Obes Metab. 
2019 Jul 12. doi: 10.1111/dom.13833. [Epub ahead of print] 
 
70. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019; 18: 
295-311.  
 
71. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide 
Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major 
Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 
2019;139: 2022-2031. 
 
72. Lotfy M, Singh J, Kalász H, et al. Medicinal Chemistry and Applications of Incretins and 
DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Open Med Chem J. 2011; 
5(Suppl 2): 82-92. 
 
73. Lotfy M, Singh J, Kalász H, et al. Medicinal Chemistry and Applications of Incretins and 














Information Classification: General 
74. Li J, Gong Y, Li C, et al. Long-term efficacy and safety of sodium-glucose cotransporter-
2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes 
mellitus: A meta-analysis. Medicine (Baltimore) 2017; 96:e7201.  
 
75. Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: 
a complementary approach to the treatment of type 2 diabetes. Postgrad Med 2017; 
129:686-697.  




Table 1: List of SGLT 1 and 2 inhibitors that are currently approved by the FDA and 
EMA 
 
Generic name Pharmacodynamics Primary 
metabolite (s) 





Dapagliflozin  10 mg/day results in 




13.8 h at 50 
mg dose 




Canagliflozin  100 mg caused 











Empagliflozin  25 mg/day induced 
93 g of glucose 
excretion 
Empagliflozin-
2-O, 3-O-, and 
6-O-
glucuronide. 






Ertugliflozin 15 mg/day induced 















Table 2: SGLT 1 and 2 drugs in the early phase of clinical trials for the treatment of DM 
 









Ipragliflozin  300 mg/day induced 





12   25, 50 
 
Phase III 35-37 
Tofogliflozin  Dose-dependent 
increase in glucose 
excretion 
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Sotagliflozin  400 mg/day induced 





29  300  Phase III 39-42 
Ertugliflozin 15 mg/day induced 







16   5, 15 Phase III 43 
Luseogliflozin  25 mg/day induced 





9 - 13  2.5, 5 Phase III 44 
Remogliflozin 1000 mg/day 
induced 130 mg of 
glucose excretion 
GSK279782 2-4  250 Phase III 45-48 
Velagliflozin Unknown  Velagliflozin 
-glucuronide 
Unknown  Phase II 49 
Henagliflozin 20 mg day induced 




9 -14 5, 10, 20 Phase I 50 
Bexagliflozin Unknown Unknown Unknown 5, 10, 20 Phase III 51 
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Figure 1. Chemical structure of SGLT2 inhibitors that have been approved by the United States Food and 
Drug Administration and the European Medicines Agency 
 
Figure 2A. Chemical structure of SGLT inhibitors that have not been approved by the United States Food 
and Drug Administration and the European Medicines Agency 
 
Figure 2B. Chemical structure of SGLT inhibitors that have not been approved by the United States Food 
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Figure 2B 
